CHY Stock Overview
Engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
ChemoMetec A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 60.00 |
| 52 Week High | DKK 73.15 |
| 52 Week Low | DKK 37.56 |
| Beta | 1.26 |
| 11 Month Change | 2.74% |
| 3 Month Change | 16.28% |
| 1 Year Change | 26.16% |
| 33 Year Change | -57.02% |
| 5 Year Change | 84.90% |
| Change since IPO | 243.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| CHY | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -13.1% | -5.2% | -0.5% |
| 1Y | 26.2% | 2.8% | 8.3% |
Return vs Industry: CHY exceeded the German Life Sciences industry which returned 2.8% over the past year.
Return vs Market: CHY exceeded the German Market which returned 8.3% over the past year.
Price Volatility
| CHY volatility | |
|---|---|
| CHY Average Weekly Movement | 11.9% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CHY's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CHY's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 174 | Martin Behrens | chemometec.com |
ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202, a consistent cell counter; NucleoCounter NC-200, an automated cell counter that provides solution for cell counting and cell viability determination; NucleoCounter SP-100, an automated sperm cell counter for use in animal reproduction; and XcytoMatic 40, a cell density and viability analyzer.
ChemoMetec A/S Fundamentals Summary
| CHY fundamental statistics | |
|---|---|
| Market cap | €1.04b |
| Earnings (TTM) | €18.27m |
| Revenue (TTM) | €54.68m |
57.2x
P/E Ratio19.1x
P/S RatioIs CHY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHY income statement (TTM) | |
|---|---|
| Revenue | DKK 407.87m |
| Cost of Revenue | DKK 40.28m |
| Gross Profit | DKK 367.60m |
| Other Expenses | DKK 231.31m |
| Earnings | DKK 136.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 05, 2025
| Earnings per share (EPS) | 7.83 |
| Gross Margin | 90.13% |
| Net Profit Margin | 33.41% |
| Debt/Equity Ratio | 0.2% |
How did CHY perform over the long term?
See historical performance and comparison